Travere Therapeutics, Inc. (TVTX)

In the past six months, Travere Therapeutics' stock has experienced significant events. The stock's 52-week range has been between $12.91 and $42.13. Travere Therapeutics reported strong Q3 2025 earnings and FY25 outlook. The FDA extended the review timeline for FILSPARI in FSGS, causing the stock to slump. There has been notable insider selling activity. Analysts generally maintain a "Moderate Buy" consensus rating for TVTX, with an average 12-month price target of approximately $38.86.

Based on the available information, there is no explicit mention of demand seasonality for Travere Therapeutics' products and services. The company has reported "robust commercial momentum for Filspari" and "strong FY25 sales," indicating consistent demand, but no specific seasonal variations have been identified.

Travere Therapeutics, Inc. is a biopharmaceutical company focused on identifying, developing, commercializing, and distributing therapies for people living with rare kidney and metabolic diseases. The company's major products include FILSPARI (sparsentan) for IgAN and FSGS, Thiola and Thiola EC (tiopronin tablets) for homozygous cystinuria, Chenodal (chenodeoxycholic acid) for radiolucent gallstones, Cholbam (cholic acid capsules) for bile acid synthesis disorders and peroxisomal disorders, and Pegtibatinase (TVT-058) for classical homocystinuria.

Travere Therapeutics is headquartered in San Diego, California, and primarily delivers its therapies in the United States. The company has commercial partnerships for FILSPARI in Europe, Australia, New Zealand, Bahrain, Brazil, Chile, Israel, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates. Chugai Pharmaceutical Co. holds exclusive rights to develop and commercialize sparsentan in Japan, South Korea, and Taiwan.

Travere Therapeutics generally holds a positive reputation among analysts, with a consensus of "Moderate Buy" ratings. The FDA's extension of the review timeline for FILSPARI in FSGS has introduced regulatory risk and caused a stock slump. Robbins Geller Rudman Dowd launched an investigation into potential securities law violations. Leadership changes within the company have been noted as potentially exacerbating volatility and uncertainty.

Travere Therapeutics' ownership structure includes a mix of institutional, retail, and individual investors. Key institutional shareholders include Janus Henderson Group Plc, BlackRock, Inc., Armistice Capital, Llc, Vanguard Group Inc, Macquarie Group Ltd, Perceptive Advisors Llc, Adage Capital Partners Gp, L.l.c., State Street Corp, Fmr Llc, and VTSMX - Vanguard Total Stock Market Index Fund Investor Shares. Approximately 1.49% of the company's stock is owned by insiders. Ruth Shepley is identified as the largest individual shareholder, owning 49.00 million shares, representing 54.77% of the company. Recent insider selling activity has been observed from executives such as Jula Inrig and CEO Eric M. Dube.